Ex vivo inhibition of PAF-induced beta-thromboglobulin release in man by ABT-299, a potent PAF antagonist.
Albert
D H
DH
Abbott Laboratories, Abbott Park, Illinois 60064-3500, USA.
Magoc
T J
TJ
Kleinert
H D
HD
Sun
E
E
Reyes
A E
AE
Carter
G W
GW
Summers
J B
JB
D000293:Adolescent; D000328:Adult; D002851:Chromatography, High Pressure Liquid; D004311:Double-Blind Method; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D011355:Prodrugs / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D011726:Pyridinium Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D013056:Spectrophotometry, Ultraviolet; D013844:Thiazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D001620:beta-Thromboglobulin / Q000378:metabolism*
D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D011355:Prodrugs; D011726:Pyridinium Compounds; D013844:Thiazoles; D001620:beta-Thromboglobulin; C093306:ABT 299